摘要
目的探究米索前列醇联合缩宫素治疗产后出血的临床效果。方法选择我院妇产科2018年3月至2018年11月接受治疗的90例产后出血患者为研究对象,将患者按照其就诊的先后顺序分为对照组和试验组,各45例。对照组患者采用缩宫素子宫体注射治疗,试验组患者采用缩宫素联合米索前列醇治疗。比较两组患者治疗后产后2、24 h出血量、第三产程持续时间、不良反应发生情况、治疗前、后红细胞比容及血红蛋白水平。结果试验组患者产后2、24 h出血量少于对照组,第三产程持续时间短于对照组,差异具有统计学意义(P<0.05);试验组患者的不良反应总发生率明显低于对照组(P<0.05);治疗后,两组患者的红细胞比容及血红蛋白水平均降低,但试验组高于对照组(P<0.05)。结论产后出血患者采取米索前列醇联合缩宫素进行治疗能有效控制患者的出血量,提高患者红细胞比容及血红蛋白水平,降低临床不良反应发生率,促进患者康复,具有临床推广应用价值。
Objective To study the clinical effect of misoprostol combined with oxytocin in the treatment of postpartum hemorrhage. Methods A total of 90 patients with postpartum hemorrhage treated in obstetrics and gynecology department of our hospital from March 2018 to November 2018 were selected as the research objects. The patients were divided into control group and experimental group according to the order of treatment, with 45 cases in each group. The control group was treated with oxytocin intrauterine injection, while the experimental group was treated with oxytocin combined with misoprostol. The 2 and 24 hours postpartum hemorrhage, duration of the third stage of labor, occurrence of adverse reactions after treatment, specific volume of erythrocyte and the level of hemoglobin before and after treatment were compared between the two groups. Results The 2 and 24 hours postpartum hemorrhage in the experimental group were less than those in the control group, and the duration of the third stage of labor was shorter than that in the control group, the differences were statistically significant (P<0.05). The total incidence of adverse reactions in the experimental group was significantly lower than that in the control group (P<0.05). After treatment, the specific volume of erythrocyte and the level of hemoglobin in both groups decreased, but those in the experimental group were higher than the control group (P<0.05). Conclusion Misoprostol combined with oxytocin in the treatment of patients with postpartum hemorrhage can effectively control the amount of bleeding, improve specific volume of erythrocyte and the level of hemoglobin, reduce the incidence of clinical adverse reactions, and promote the rehabilitation of patients, which has clinical promotion and application value.
作者
左慧
ZUO Hui(Dali Maternal and Child Health Care Hospital, Dali 671000, China)
出处
《临床医学研究与实践》
2019年第31期143-144,147,共3页
Clinical Research and Practice
关键词
产后出血
缩宫素
米索前列醇
postpartum hemorrhage
oxytocin
misoprostol
